{"id":31475,"date":"2025-05-29T23:34:47","date_gmt":"2025-05-29T22:34:47","guid":{"rendered":"https:\/\/by-tv.co.uk\/?p=31475"},"modified":"2025-05-29T23:34:47","modified_gmt":"2025-05-29T22:34:47","slug":"nhs-kemoterapi-gibi-agir-tedavilerden-kacinmayi-saglayacak-dna-kan-testini-baslatiyor","status":"publish","type":"post","link":"https:\/\/by-tv.co.uk\/en\/nhs-kemoterapi-gibi-agir-tedavilerden-kacinmayi-saglayacak-dna-kan-testini-baslatiyor\/","title":{"rendered":"NHS, Kemoterapi Gibi A\u011f\u0131r Tedavilerden Ka\u00e7\u0131nmay\u0131 Sa\u011flayacak DNA Kan Testini Ba\u015flat\u0131yor"},"content":{"rendered":"

\u0130ngiltere Ulusal Sa\u011fl\u0131k Servisi (NHS), akci\u011fer ve meme kanseri hastalar\u0131 i\u00e7in t\u00fcm\u00f6r DNA\u2019s\u0131n\u0131 kandaki k\u00fc\u00e7\u00fck par\u00e7ac\u0131klar arac\u0131l\u0131\u011f\u0131yla tespit eden ve tedaviye eri\u015fimi h\u0131zland\u0131ran yeni bir s\u0131v\u0131 biyopsi testini \u00fclke genelinde kullan\u0131ma sunuyor.<\/p>\n

The Guardian<\/em> gazetesinin haberine g\u00f6re, bu “devrim niteli\u011findeki” DNA kan testi sayesinde hastalar, t\u00fcm\u00f6rlerinin genetik profiline \u00f6zel olarak geli\u015ftirilmi\u015f ila\u00e7lara daha erken ula\u015fabilecek. B\u00f6ylece hem sa\u011fkal\u0131m oranlar\u0131n\u0131n art\u0131r\u0131lmas\u0131 hem de kemoterapi gibi yo\u011fun tedavilerden ka\u00e7\u0131n\u0131lmas\u0131 hedefleniyor.<\/p>\n

H\u0131zl\u0131 Sonu\u00e7lar, Erken M\u00fcdahale<\/strong><\/h4>\n

Yeni test kapsam\u0131nda hastadan al\u0131nan kan \u00f6rne\u011fi, NHS\u2019nin Manchester ve Londra\u2019daki genetik laboratuvarlar\u0131nda analiz ediliyor. Sonu\u00e7lar birka\u00e7 g\u00fcn i\u00e7inde \u00e7\u0131k\u0131yor ve doktorlara, hastaya en uygun hedefe y\u00f6nelik tedaviyi belirlemede rehberlik ediyor.<\/p>

\"\"<\/a><\/div>\n

Pilot uygulamalarda elde edilen ba\u015far\u0131lar\u0131n ard\u0131ndan, her y\u0131l en az 15.000 \u015f\u00fcpheli akci\u011fer kanseri hastas\u0131n\u0131n bu testten faydalanmas\u0131 bekleniyor. Ayr\u0131ca ileri evre meme kanseri hastalar\u0131 i\u00e7in de kullan\u0131lacak testin, d\u00f6rt farkl\u0131 genetik varyasyonu tespit edebilece\u011fi ve y\u0131lda 5.000 kad\u0131na ki\u015fiselle\u015ftirilmi\u015f tedavi sa\u011flayaca\u011f\u0131 belirtiliyor.<\/p>\n

D\u00fcnya \u00c7ap\u0131nda Bir \u0130lk<\/strong><\/h4>\n

S\u00f6z konusu test, NHS taraf\u0131ndan ilk kez geleneksel doku biyopsilerinden \u00f6nce uygulanacak ve bu y\u00f6n\u00fcyle akci\u011fer kanserinin te\u015fhisinde \u201c\u00f6nce kan testi\u201d yakla\u015f\u0131m\u0131n\u0131 benimseyen ilk sa\u011fl\u0131k sistemi olacak.<\/p>\n

NHS \u0130ngiltere Kanserden Sorumlu Klinik Direkt\u00f6r\u00fc Prof. Peter Johnson, \u201cS\u0131v\u0131 biyopsiler ki\u015fiselle\u015ftirilmi\u015f kanser tedavisinde yeni bir d\u00f6nemin kap\u0131lar\u0131n\u0131 aral\u0131yor. Bu testin kullan\u0131m\u0131 sayesinde baz\u0131 hastalar daha yo\u011fun tedavilerden ka\u00e7\u0131nabilecek. Halihaz\u0131rda akci\u011fer ve meme kanseri hastalar\u0131nda sa\u011flad\u0131\u011f\u0131 fayday\u0131 g\u00f6rd\u00fck ve bu y\u00f6ntemi di\u011fer kanser t\u00fcrlerine de geni\u015fletmeyi hedefliyoruz,\u201d dedi.<\/p>\n

\u00a311 Milyon Tasarruf ve Artan Ya\u015fam Kalitesi<\/strong><\/h4>\n

Pilot \u00e7al\u0131\u015fmalar\u0131n ekonomik analizine g\u00f6re, testin yaln\u0131zca akci\u011fer kanseri alan\u0131nda NHS\u2019ye y\u0131ll\u0131k yakla\u015f\u0131k \u00a311 milyon tasarruf sa\u011flamas\u0131 bekleniyor. Ayr\u0131ca testin, hastalar\u0131n gereksiz tan\u0131 i\u015flemlerine ve kemoterapi gibi yan etkili tedavilere maruz kalmas\u0131n\u0131 \u00f6nleyerek ya\u015fam kalitelerini art\u0131rd\u0131\u011f\u0131 da bildirildi.<\/p>\n

Ulusal Yayg\u0131nla\u015ft\u0131rma Ba\u015flad\u0131<\/strong><\/h4>\n

\u0130ngiltere’nin Ba\u015f Bilim Yetkilisi Prof. Dame Sue Hill, \u201cBu test, kanserli h\u00fccrelerin kana kar\u0131\u015fan genetik par\u00e7ac\u0131klar\u0131n\u0131 tespit ederek, hedefe y\u00f6nelik ila\u00e7lar\u0131n daha h\u0131zl\u0131 ve hassas bir \u015fekilde uygulanmas\u0131n\u0131 sa\u011fl\u0131yor. NHS, genetik teknolojilerdeki son geli\u015fmeleri hasta hizmetine entegre etmeye devam ediyor,\u201d dedi.<\/p>\n

Test, t\u00fcm uygun akci\u011fer ve meme kanseri hastalar\u0131na \u0130ngiltere genelindeki NHS hastanelerinde sunulacak.<\/p>\n

Daha Fazla Kanser T\u00fcr\u00fcne Uygulanmas\u0131 Hedefleniyor<\/strong><\/h4>\n

S\u0131v\u0131 biyopsi y\u00f6ntemi, yak\u0131n gelecekte pankreas ve safra kesesi kanserleri gibi di\u011fer kanser t\u00fcrlerine de uygulanmak \u00fczere de\u011ferlendiriliyor. Newcastle upon Tyne Hastaneleri NHS Vakf\u0131’ndan Prof. Alastair Greystoke, bu y\u00f6ntemin ulusal d\u00fczeyde ilk kez uygulanmas\u0131n\u0131n hem hastalara hem de sa\u011fl\u0131k sistemine \u00f6nemli katk\u0131lar sundu\u011funu vurgulad\u0131.<\/p>\n

Royal Marsden Hastanesi\u2019nden Prof. Sanjay Popat ise, \u201cBu testin uygulanmas\u0131 sayesinde hastalar tedaviye daha erken ba\u015fl\u0131yor ve kendileri i\u00e7in en uygun ilac\u0131 alabiliyor. Bu, \u0130ngiltere\u2019de kanser hastalar\u0131 i\u00e7in b\u00fcy\u00fck bir ilerleme,\u201d ifadelerini kulland\u0131.<\/p>\n

\"\"<\/a><\/div>","protected":false},"excerpt":{"rendered":"

\u0130ngiltere Ulusal Sa\u011fl\u0131k Servisi (NHS), akci\u011fer ve meme kanseri hastalar\u0131 i\u00e7in t\u00fcm\u00f6r DNA\u2019s\u0131n\u0131 kandaki k\u00fc\u00e7\u00fck par\u00e7ac\u0131klar arac\u0131l\u0131\u011f\u0131yla tespit eden ve tedaviye eri\u015fimi h\u0131zland\u0131ran yeni bir s\u0131v\u0131 biyopsi testini \u00fclke genelinde kullan\u0131ma sunuyor. The Guardian gazetesinin haberine g\u00f6re, bu “devrim niteli\u011findeki” DNA kan testi sayesinde hastalar, t\u00fcm\u00f6rlerinin genetik profiline \u00f6zel olarak geli\u015ftirilmi\u015f ila\u00e7lara daha erken ula\u015fabilecek. B\u00f6ylece hem sa\u011fkal\u0131m oranlar\u0131n\u0131n art\u0131r\u0131lmas\u0131 hem de kemoterapi gibi yo\u011fun tedavilerden ka\u00e7\u0131n\u0131lmas\u0131 hedefleniyor. H\u0131zl\u0131 Sonu\u00e7lar, Erken M\u00fcdahale Yeni test kapsam\u0131nda hastadan al\u0131nan kan \u00f6rne\u011fi, NHS\u2019nin Manchester ve Londra\u2019daki genetik laboratuvarlar\u0131nda analiz ediliyor. Sonu\u00e7lar birka\u00e7 g\u00fcn i\u00e7inde \u00e7\u0131k\u0131yor ve doktorlara, hastaya en uygun hedefe y\u00f6nelik tedaviyi […]<\/p>\n","protected":false},"author":1,"featured_media":29271,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"ngg_post_thumbnail":0,"footnotes":""},"categories":[5269],"tags":[],"class_list":["post-31475","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-birlesik-krallik"],"_links":{"self":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/31475","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/comments?post=31475"}],"version-history":[{"count":0,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/posts\/31475\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media\/29271"}],"wp:attachment":[{"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/media?parent=31475"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/categories?post=31475"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/by-tv.co.uk\/en\/wp-json\/wp\/v2\/tags?post=31475"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}